{
  "openalex_id": "W2911917895",
  "doi": "https://doi.org/10.2147/ott.s187739",
  "title": "&lt;p&gt;Efficacy and safety of targeted therapy for metastatic HER2-positive breast cancer in the first-line treatment: a Bayesian network meta-analysis&lt;/p&gt;",
  "abstract": "Purpose: Numerous HER2-targeted therapy clinical trials have demonstrated efficacy and safety in the first-line treatment of metastatic breast cancer (MBC). However, the direct or indirect comparison of these drugs is unclear. This network meta-analysis can solve this issue to some extent. Materials and methods: PubMed, Embase, and the Cochrane Library were searched for Phase II/III randomized controlled trials (RCTs) on metastatic HER2-positive breast cancer for first-line treatment up to December 16, 2017. Paired meta-analyses were performed to compare the regimens directly with the TP (trastuzumab plus taxane) regimen. Bayesian network meta-analysis was used to synthesize available evidence of direct or indirect comparison. Results: The database search identified 1,935 articles, among which 13 articles (10 RCTs) were eligible for the analysis involving 5,177 patients treated with 11 different regimens. The progression-free survival (PFS) in the Bayesian network meta-analysis suggested that the PTP (pertuzumab and trastuzumab plus taxane) regimen had the highest probability to be the preferred treatment (surface under the cumulative ranking [SUCRA]: 0.967) followed by the TPC (carboplatin and trastuzumab plus taxane) regimen (SUCRA: 0.923). The PTP regimen (SUCRA: 0.926) was similarly preferred for overall survival (OS). For objective response rate (ORR), the PTC regimen might be the optimal treatment (SUCRA: 0.935), followed by the PTP regimen. Conclusion: Overall, PTP might be the optimal first-line treatment for HER-2-positive MBC to improve the PFS and OS. Meanwhile, TPC might be most effective treatment in terms of the ORR. Regarding safety, the two regimens showed acceptable grade 3 or greater hematologic toxicity and heart failure. Keywords: breast cancer, metastasis, HER2-positive, HER2-targeted agents, network meta-analysis, randomized controlled trial",
  "authors": [
    {
      "display_name": "Fubin Feng",
      "id": "A5027151363",
      "orcid": "https://orcid.org/0000-0002-1586-638X",
      "institutions": [
        {
          "id": "I4210159744",
          "display_name": "Weifang Chinese Medicine Hospital",
          "country_code": "CN",
          "type": "healthcare"
        }
      ],
      "is_corresponding": false,
      "raw_author_name": "Fubin Feng"
    },
    {
      "display_name": "Tingting Zhang",
      "id": "A5100329609",
      "orcid": "https://orcid.org/0000-0001-9141-2593",
      "institutions": [
        {
          "id": "I134738993",
          "display_name": "Shandong University of Traditional Chinese Medicine",
          "country_code": "CN",
          "type": "education"
        }
      ],
      "is_corresponding": false,
      "raw_author_name": "Tingting Zhang"
    },
    {
      "display_name": "Fang Yin",
      "id": "A5042717314",
      "orcid": "https://orcid.org/0009-0006-3713-6130",
      "institutions": [
        {
          "id": "I4210113011",
          "display_name": "Weifang People's Hospital",
          "country_code": "CN",
          "type": "healthcare"
        }
      ],
      "is_corresponding": false,
      "raw_author_name": "Fang Yin"
    },
    {
      "display_name": "Cun Liu",
      "id": "A5059351364",
      "orcid": "https://orcid.org/0000-0001-8197-9000",
      "institutions": [
        {
          "id": "I134738993",
          "display_name": "Shandong University of Traditional Chinese Medicine",
          "country_code": "CN",
          "type": "education"
        }
      ],
      "is_corresponding": false,
      "raw_author_name": "Cun Liu"
    },
    {
      "display_name": "Jing Zhuang",
      "id": "A5101596509",
      "orcid": "https://orcid.org/0000-0002-2641-8611",
      "institutions": [
        {
          "id": "I4210159744",
          "display_name": "Weifang Chinese Medicine Hospital",
          "country_code": "CN",
          "type": "healthcare"
        }
      ],
      "is_corresponding": false,
      "raw_author_name": "Jing Zhuang"
    },
    {
      "display_name": "Lingyu Qi",
      "id": "A5090683832",
      "orcid": "https://orcid.org/0000-0002-7167-776X",
      "institutions": [
        {
          "id": "I134738993",
          "display_name": "Shandong University of Traditional Chinese Medicine",
          "country_code": "CN",
          "type": "education"
        }
      ],
      "is_corresponding": false,
      "raw_author_name": "Lingyu Qi"
    },
    {
      "display_name": "Xue Wang",
      "id": "A5103069310",
      "orcid": "https://orcid.org/0009-0008-2963-0352",
      "institutions": [
        {
          "id": "I108688024",
          "display_name": "Qingdao University",
          "country_code": "CN",
          "type": "funder"
        }
      ],
      "is_corresponding": false,
      "raw_author_name": "Xue Wang"
    },
    {
      "display_name": "Jia Li",
      "id": "A5100629778",
      "orcid": "https://orcid.org/0000-0003-1076-4496",
      "institutions": [
        {
          "id": "I117331123",
          "display_name": "Weifang Medical University",
          "country_code": "CN",
          "type": "funder"
        }
      ],
      "is_corresponding": false,
      "raw_author_name": "Jia Li"
    },
    {
      "display_name": "Lu Wang",
      "id": "A5100364404",
      "orcid": "https://orcid.org/0000-0001-8689-6108",
      "institutions": [
        {
          "id": "I4210159744",
          "display_name": "Weifang Chinese Medicine Hospital",
          "country_code": "CN",
          "type": "healthcare"
        }
      ],
      "is_corresponding": false,
      "raw_author_name": "Lu Wang"
    },
    {
      "display_name": "Jinhui Tian",
      "id": "A5101682921",
      "orcid": "https://orcid.org/0000-0002-0054-2454",
      "institutions": [
        {
          "id": "I76214153",
          "display_name": "Lanzhou University",
          "country_code": "CN",
          "type": "funder"
        }
      ],
      "is_corresponding": false,
      "raw_author_name": "Jinhui Tian"
    },
    {
      "display_name": "Changgang Sun",
      "id": "A5085240510",
      "orcid": "https://orcid.org/0000-0003-0778-8788",
      "institutions": [
        {
          "id": "I117331123",
          "display_name": "Weifang Medical University",
          "country_code": "CN",
          "type": "funder"
        }
      ],
      "is_corresponding": false,
      "raw_author_name": "Changgang Sun"
    }
  ],
  "publication_year": 2019,
  "publication_date": "2019-01-01",
  "type": "article",
  "cited_by_count": 10,
  "is_retracted": false,
  "is_paratext": false,
  "language": "en",
  "source": {
    "id": "S120324992",
    "display_name": "OncoTargets and Therapy",
    "issn_l": "1178-6930",
    "issn": [
      "1178-6930"
    ],
    "type": "journal",
    "host_organization": "https://openalex.org/P4310320348"
  },
  "volume": "Volume 12",
  "issue": null,
  "first_page": "959",
  "last_page": "974",
  "open_access": {
    "is_oa": true,
    "oa_status": "gold",
    "oa_url": "https://www.dovepress.com/getfile.php?fileID=47816",
    "any_repository_has_fulltext": true
  },
  "concepts": [
    {
      "id": "C71924100",
      "display_name": "Medicine",
      "level": 0,
      "score": 0.7391406
    },
    {
      "id": "C95190672",
      "display_name": "Meta-analysis",
      "level": 2,
      "score": 0.7382662
    },
    {
      "id": "C143998085",
      "display_name": "Oncology",
      "level": 1,
      "score": 0.64956427
    },
    {
      "id": "C2777329042",
      "display_name": "Lapatinib",
      "level": 5,
      "score": 0.6048535
    },
    {
      "id": "C2775930923",
      "display_name": "Metastatic breast cancer",
      "level": 4,
      "score": 0.59632045
    },
    {
      "id": "C530470458",
      "display_name": "Breast cancer",
      "level": 3,
      "score": 0.565818
    },
    {
      "id": "C126322002",
      "display_name": "Internal medicine",
      "level": 1,
      "score": 0.5600381
    },
    {
      "id": "C2781230642",
      "display_name": "Targeted therapy",
      "level": 3,
      "score": 0.4135336
    },
    {
      "id": "C121608353",
      "display_name": "Cancer",
      "level": 2,
      "score": 0.37873372
    },
    {
      "id": "C2779786085",
      "display_name": "Trastuzumab",
      "level": 4,
      "score": 0.3655542
    }
  ],
  "topics": [
    {
      "id": "T10755",
      "display_name": "HER2/EGFR in Cancer Research",
      "score": 0.9999
    },
    {
      "id": "T11752",
      "display_name": "Cancer Treatment and Pharmacology",
      "score": 0.9983
    },
    {
      "id": "T10183",
      "display_name": "Breast Cancer Treatment Studies",
      "score": 0.9906
    }
  ],
  "created_date": null,
  "updated_date": null,
  "indexed_in": [],
  "landing_page_url": "https://doi.org/10.2147/ott.s187739",
  "pdf_url": "https://www.dovepress.com/getfile.php?fileID=47816",
  "retrieved_date": "2025-07-30T15:05:08.490717",
  "source_database": "OpenAlex"
}